Tidal Investments LLC Increases Holdings in Hologic, Inc. (NASDAQ:HOLX)

Tidal Investments LLC boosted its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 38.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,223 shares of the medical equipment provider's stock after acquiring an additional 5,872 shares during the period. Tidal Investments LLC's holdings in Hologic were worth $1,530,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Venturi Wealth Management LLC boosted its holdings in Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after acquiring an additional 261 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after buying an additional 260 shares in the last quarter. Smartleaf Asset Management LLC boosted its holdings in shares of Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after buying an additional 159 shares in the last quarter. Smithfield Trust Co boosted its holdings in shares of Hologic by 160.0% during the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock worth $45,000 after buying an additional 400 shares in the last quarter. Finally, Raiffeisen Bank International AG bought a new position in shares of Hologic during the 4th quarter worth approximately $49,000. 94.73% of the stock is currently owned by institutional investors.

Insider Activity

In other Hologic news, Director Martin D. Madaus bought 5,445 shares of the firm's stock in a transaction dated Wednesday, May 7th. The stock was purchased at an average cost of $55.24 per share, with a total value of $300,781.80. Following the transaction, the director now directly owns 5,445 shares in the company, valued at $300,781.80. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.88% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on HOLX shares. Raymond James restated an "outperform" rating and set a $71.00 price target (down from $90.00) on shares of Hologic in a report on Friday, May 2nd. William Blair restated an "outperform" rating on shares of Hologic in a report on Thursday, February 6th. Wall Street Zen cut Hologic from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Leerink Partners cut Hologic from an "outperform" rating to a "market perform" rating and cut their price target for the stock from $80.00 to $75.00 in a report on Thursday, February 6th. Finally, Needham & Company LLC restated a "hold" rating on shares of Hologic in a report on Tuesday. Twelve research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $77.42.

Hologic Stock Down 1.0%

NASDAQ HOLX traded down $0.62 on Thursday, reaching $63.10. The company had a trading volume of 860,757 shares, compared to its average volume of 2,239,051. The stock has a market capitalization of $14.06 billion, a P/E ratio of 19.88, a P/E/G ratio of 2.14 and a beta of 0.54. The company's fifty day moving average is $58.09 and its 200 day moving average is $66.21. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.67. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. During the same period in the prior year, the firm posted $1.03 EPS. Hologic's quarterly revenue was down 1.2% compared to the same quarter last year. Sell-side analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.